A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

By sjmartinez • July 3, 2025

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Jul 1;199:96-102. doi: 10.1016/j.ygyno.2025.06.014. Epub ahead of print. PMID: 40602355.

Tags: Bevacizumab, Hematology/Oncology, maintenance therapy, Niraparib, ovarian cancer, Publications

Related Posts

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T,[...]

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Cho SB, Hsu CH, Huang[...]

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of[...]